[go: up one dir, main page]

WO1996024345A3 - Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten - Google Patents

Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten Download PDF

Info

Publication number
WO1996024345A3
WO1996024345A3 PCT/DE1996/000183 DE9600183W WO9624345A3 WO 1996024345 A3 WO1996024345 A3 WO 1996024345A3 DE 9600183 W DE9600183 W DE 9600183W WO 9624345 A3 WO9624345 A3 WO 9624345A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
substance
group
blood
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1996/000183
Other languages
English (en)
French (fr)
Other versions
WO1996024345A2 (de
Inventor
Martin Kohlmeier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19504003A external-priority patent/DE19504003A1/de
Application filed by Individual filed Critical Individual
Priority to AU46186/96A priority Critical patent/AU4618696A/en
Priority to EP96901702A priority patent/EP0759748A1/de
Publication of WO1996024345A2 publication Critical patent/WO1996024345A2/de
Publication of WO1996024345A3 publication Critical patent/WO1996024345A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Vorgeschlagen wird eine neue Verwendung eines Vitamins der K-Gruppe oder einer den Transport eines Vitamins der K-Gruppe beeinflussenden Substanz oder einer die Regenerierung eines Vitamins der K-Gruppe aktivierenden Substanz zu Herstellung eines Präparates gegen einen beschleunigten Verlust kognitiver Fähigkeiten, insbesondere gegen Auswirkungen von Alzheimer'scher Demenz. Zur Herstellung eines Präparates zur Abschätzung des Entstehungsrisikos eines beschleunigten Verlustes kognitiver Fähigkeiten bzw. für Alzheimer'sche Demenz werden ferner vorgeschlagen die Verwendung einer Substanz, mit der die Konzentration von Vitamin K in Blut oder anderen Körperflüssigkeiten bestimmbar ist, die Verwendung einer Substanz, mit der der Anteil an carboxylierten Glutamatresten in Vitamin K-abhängigen Proteinen in Blut oder anderen Körperflüssigkeiten bestimmbar ist und die Verwendung einer Substanz, mit der die Konzentration von η-carboxy-Glutamat in Blut oder anderen Körperflüssigkeiten oder in Ausscheidungen bestimmbar ist.
PCT/DE1996/000183 1995-02-08 1996-02-07 Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten Ceased WO1996024345A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU46186/96A AU4618696A (en) 1995-02-08 1996-02-07 Uses of a vitamin of the k-group against a loss of cognitive faculties
EP96901702A EP0759748A1 (de) 1995-02-08 1996-02-07 Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19504003.1 1995-02-08
DE19504003A DE19504003A1 (de) 1995-02-08 1995-02-08 Verwendungen eines Vitamins der K-Gruppe

Publications (2)

Publication Number Publication Date
WO1996024345A2 WO1996024345A2 (de) 1996-08-15
WO1996024345A3 true WO1996024345A3 (de) 1997-02-20

Family

ID=7753374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1996/000183 Ceased WO1996024345A2 (de) 1995-02-08 1996-02-07 Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten

Country Status (4)

Country Link
EP (1) EP0759748A1 (de)
AU (1) AU4618696A (de)
DE (1) DE19549262C2 (de)
WO (1) WO1996024345A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646429B (zh) * 2007-04-05 2012-08-29 J-制油株式会社 镇定剂及功能性食品

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366480A2 (de) * 1988-10-27 1990-05-02 Bar Ilan University Verfahren und Mittel zur Behandlung der Alzheimer-Krankheit, verwandter Demenzen und Epilepsie
US5059627A (en) * 1989-08-24 1991-10-22 Takeda Chemical Industries, Ltd. Nerve growth factor secretion inducing composition
WO1991016047A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5h)-furanones as anti-inflammatory agents
JPH06340526A (ja) * 1993-06-02 1994-12-13 Mitsui Toatsu Chem Inc 置換１，４−ナフトキノン誘導体を有効成分として含有する神経成長因子産生、分泌誘発剤
EP0629400A1 (de) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438208A (en) * 1982-05-27 1984-03-20 The Regents Of The University Of California Region-specific determinants for vitamin K dependent bone protein
EP0118256B1 (de) * 1983-03-04 1992-05-13 Scripps Clinic And Research Foundation Immunoadsorbens und Verfahren zur Zurückgewinnung von Vitamin-K-abhängigen Proteinen mittels dieses Adsorbens
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
FR2678638A1 (fr) * 1991-07-03 1993-01-08 Inst Nat Sante Rech Med Anticorps polyclonaux et monoclonaux contre la proteine tau pour le diagnostic de la maladie d'alzheimer.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366480A2 (de) * 1988-10-27 1990-05-02 Bar Ilan University Verfahren und Mittel zur Behandlung der Alzheimer-Krankheit, verwandter Demenzen und Epilepsie
US5059627A (en) * 1989-08-24 1991-10-22 Takeda Chemical Industries, Ltd. Nerve growth factor secretion inducing composition
WO1991016047A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5h)-furanones as anti-inflammatory agents
JPH06340526A (ja) * 1993-06-02 1994-12-13 Mitsui Toatsu Chem Inc 置換１，４−ナフトキノン誘導体を有効成分として含有する神経成長因子産生、分泌誘発剤
EP0629400A1 (de) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9509, Derwent World Patents Index; AN 95-063774, XP002011185 *
M.J. SHEARER: "Vitamin K metabolism and nutriture", BLOOD REV., vol. 6, no. 2, 1992, pages 92 - 104, XP002011184 *
R.B. RUCKER ET AL.: "New perspectives on function of vitamins", NUTRITION, vol. 10, no. 6, 1994, pages 507 - 513, XP002011183 *

Also Published As

Publication number Publication date
WO1996024345A2 (de) 1996-08-15
DE19549262C2 (de) 1997-10-09
EP0759748A1 (de) 1997-03-05
DE19549262A1 (de) 1996-09-05
AU4618696A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
ZA9810444B (en) Use of 9-deoxy-2',9-methano-3-oxa-4,5,6-trinor-3,7-(1',3'interphenylene)-13,14-dihydroprostaglandin F1 to treat peripheral vascular disease
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
AU1917095A (en) 6-substituted mycophenolic and derivatives with immunosuppressive activity
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
DE68903516D1 (de) Mittel zur senkung des blutdrucks.
EP0850648A3 (de) Zusammensetzungen aus einer thrombolytisch wirkende Substanz und Antikoagulantien, und ihre Verwendungen
WO1996019580A3 (en) Telomerase protein component
TR199700872A2 (xx) Kompleks lipid' lerin kullan�lmas�.
EP1053315A4 (de) Menschliches 'haarlos'-gen und -protein und ihre verwendungen
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
EE9800066A (et) Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis
WO1996024345A3 (de) Verwendung eines vitamins der k-gruppe gegen einen verlust kognitiver fähigkeiten
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
EP0373771A3 (de) Neue pharmazeutische Anwendungen von Cystatinen
ES2176523T3 (es) Procedimiento para la deteccion de la enfermedad de alzheimer.
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
WO1998011246A3 (en) ENDO-β-GALACTOSIDASE
WO1996032133A3 (de) Konjugat zur behandlung von entzündungs-, infektions- und/oder hauterkrankungen
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
EP0778027A3 (de) Verwendung von Kieselerde zur Herstellung von Arzneimitteln
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
Jones No more use for general anaesthesia
Castrogiovanni et al. Platelet phenol sulphotransferase: A peripheral marker of the dopamine system?
Gunderson et al. " Borderline personality disorder and depression": Reply.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1996901702

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 1996901702

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996901702

Country of ref document: EP